Table 1.
Variable | |
---|---|
Age at enrollment, years [mean (SD)] | 50.1 (14.2) |
Gender [n (%)] | |
Female | 37 (39.8) |
Male | 56 (60.2) |
Race or ethnic group [n (%)] | |
White | 87 (93.5) |
Black | 3 (3.2) |
Other | 3 (3.2) |
Ethnic group [n (%)] | |
Not Hispanic or Latino | 90 (96.7) |
Hispanic or Latino | 2 (2.2) |
Unknown | 1 (1.1) |
ANCA-associated vasculitis type [n (%)] | |
Granulomatosis with polyangiitis | 90 (96.7) |
Microscopic polyangiitis | 3 (3.2) |
Newly diagnosed at enrollment [n (%)] | 41 (44.1) |
Organ involvement at enrollment, by BVAS/WG [n (%)] | |
Ear, nose, and throat | 70 (75.3) |
Constitutional | 65 (69.9) |
Renal | 60 (64.5) |
Pulmonary | 50 (53.7) |
Mucous membranes and eyes | 31 (33.3) |
Cutaneous | 20 (21.5) |
Nervous system | 19 (20.4) |
Cardiovascular | 1 (1.1) |
Gastrointestinal | 1 (1.1) |
Other | 7 (7.5) |
BVAS/WG at enrollment [mean (SD)] | 8.1 (3.1) |
ESR at enrollment, mm/hr [mean (SD)] | 36.0 (28.6) |
CRP at enrollment, mg/dL [mean (SD)] | 5.0 (12.4) |
Creatinine at enrollment, mg/dL [mean (SD)] | 1.0 (0.65) |
Treatment group | |
Rituximab [n (%)] | 50 (53.7) |
Cyclophosphamide [n (%)] | 43 (46.2) |
Time to CR, months [median (IQR)] | 5.9 (5.8 – 6.2) |
Duration of follow-up after CR, months [median (IQR)] | 35.6 (24.6 – 42.6) |
SD, standard deviation; n, number; ANCA, antineutrophil cytoplasmic antibody; BVAS/WG, Birmingham Vasculitis Activity Score for Wegener Granulomatosis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CR, complete remission; IQR, interquartile range (25-75%)